Notable ETF Inflow Detected - SCZ, TIGO, ODD, CLBT

Written by Emily J. Thompson, Senior Investment Analyst

ODD+1.08%

SCZ+0.55%

CLBT+0.32%

Source: NASDAQ.COM

Updated: May 09 2025

0mins

Source: NASDAQ.COM

52 Week Range and Current Price: SCZ's share price is currently at $68.18, within a 52-week range of $56.64 to $68.325, with the 200-day moving average being a useful tool for analysis.
ETFs Trading Dynamics: ETFs function similarly to stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings and market dynamics.

ODD

$35.42+Infinity%1D

Analyst Views on ODD

Wall Street analysts forecast ODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ODD is 66.63 USD with a low forecast of 49.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Analyst Rating

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 35.040

Low

49.00

Averages

66.63

High

80.00

Current: 35.040

Low

49.00

Averages

66.63

High

80.00

Barclays

Lauren Lieberman

Equal Weight

downgrade

$46 -> $40

2026-01-16

Reason

Barclays

Lauren Lieberman

Price Target

$46 -> $40

AI Analysis

2026-01-16

downgrade

Equal Weight

Reason

Barclays analyst Lauren Lieberman lowered the firm's price target on Oddity to $40 from $46 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the consumer staples group as part of a Q4 earnings preview. Barclays attributes the recent "enthusiasm" in the stock to "a flight to safety" and remains concerned about company- and sector-level fundamentals. Potential oil and currency headwinds could materialize in 2026, the analyst tells investors in a research note.

KeyBanc

Overweight

downgrade

$70 -> $50

2026-01-08

Reason

KeyBanc

Price Target

$70 -> $50

2026-01-08

downgrade

Overweight

Reason

KeyBanc lowered the firm's price target on Oddity to $50 from $70 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ODD

Unlock Now

JPMorgan

Cory Carpenter

Overweight -> Overweight

downgrade

$67 -> $59

2025-12-12

Reason

JPMorgan

Cory Carpenter

Price Target

$67 -> $59

2025-12-12

downgrade

Overweight -> Overweight

Reason

JPMorgan analyst Cory Carpenter lowered the firm's price target on Oddity to $59 from $67 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the small- and mid-cap internet and video games group as part of its 2026 outlook.

Morgan Stanley

Equal Weight

downgrade

$61 -> $49

2025-11-21

Reason

Morgan Stanley

Price Target

$61 -> $49

2025-11-21

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Oddity to $49 from $61 and keeps an Equal Weight rating on the shares. Near-term delivery remains "impressive" in a difficult environment and Oddity continued to "bless" its long-term algorithm for FY26, but not give official guidance, the analyst tells investors. The firm, which is rolling its valuation basis forward one year, notes that its lower multiple reflects a more uncertain U.S. environment applied to EBITDA estimates that remain "relatively unchanged."

About ODD

Oddity Tech Ltd is an Israel-based company engaged in the beauty and wellness sector. The Company is operating a tech platform under its own brand on the Internet, whose purpose is to support a portfolio of brands and services connected to the beauty and wellness market and to develop products customized to the wishes of the Company's clients. The Company is using algorithms and machine learning models to match a corresponding physical product. Advanced biological models and machine learning-based tools are used to find new molecules for beauty and wellness purposes. The Company is active in research and development in areas such as data science, machine learning, and computer vision to enhance its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.